Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
HIMS
HIMS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HIMS News
Hims & Hers Faces Key Regulatory Meeting on Peptides
2d ago
stocktwits
Hims & Hers Partners with Novo Nordisk, Boosting Stock Momentum
2d ago
stocktwits
Hims' Peptide Market Outlook for the Next Decade
3d ago
stocktwits
Regentis Soars After Withdrawing US Listing Application
4d ago
NASDAQ.COM
Hims & Hers Stock Surges 12.49% Amid Obesity Market Optimism
4d ago
Yahoo Finance
HIMS Shares Eye Breakout Above $30 Resistance Level
4d ago
stocktwits
Mammoth Brands Takes on Traditional CPG Giants
Jun 07 2026
CNBC
Hims & Hers Health Faces Challenges and Opportunities
Jun 05 2026
NASDAQ.COM
TD Cowen Raises Global GLP-1 Sales Forecast Significantly
Jun 05 2026
stocktwits
Hims & Hers Aims to Expand Healthcare Platform Amid Challenges
Jun 05 2026
Fool
Hims Launches Healthcare Super App, AI Drives Health Transformation
Jun 05 2026
stocktwits
Hims & Hers Appoints New Chief Medical Officer
Jun 04 2026
NASDAQ.COM
HIMS Reiterates Buy Rating with $32 Price Target, 16% Upside
Jun 04 2026
stocktwits
Hims & Hers Faces Uncertainty Over GLP-1 Drug Profits
Jun 03 2026
stocktwits
Hims & Hers Completes Acquisition of Eucalyptus for $240M
Jun 02 2026
seekingalpha
Hims & Hers Acquires Eucalyptus to Expand Canadian Market Reach
Jun 02 2026
Newsfilter
Show More News
